Interestingly, despite the lack of epidemiological as well as clinical studies of circulating IGF-1 in relation to lung disease, substantial preclinical evidence has revealed the potential effects of IGF-1 in the pathobiology of asthma, COPD, lung cancers, and IPF. This evidence concerns the gene IGF1 and lung carcinoma.